Cargando…
Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy
Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide. Surgery, liver transplantation, and ablation therapies have been used to treat early HBV-caused HCC (HBV...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059020/ https://www.ncbi.nlm.nih.gov/pubmed/36992198 http://dx.doi.org/10.3390/vaccines11030614 |
_version_ | 1785016775064158208 |
---|---|
author | Zhang, Jin Hu, Changwei Xie, Xiaoxiao Qi, Linzhi Li, Chuanzhou Li, Shangze |
author_facet | Zhang, Jin Hu, Changwei Xie, Xiaoxiao Qi, Linzhi Li, Chuanzhou Li, Shangze |
author_sort | Zhang, Jin |
collection | PubMed |
description | Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide. Surgery, liver transplantation, and ablation therapies have been used to treat early HBV-caused HCC (HBV-HCC); meanwhile, in the advanced stage, chemoradiotherapy and drug-targeted therapy are regularly considered, but with limited efficacy. Recently, immunotherapies, such as tumor vaccine therapy, adoptive cell transfer therapy, and immune checkpoint inhibitor therapy, have demonstrated promising efficacy in cancer treatment. In particular, immune checkpoint inhibitors can successfully prevent tumors from achieving immune escape and promote an anti-tumor response, thereby boosting the therapeutic effect in HBV-HCC. However, the advantages of immune checkpoint inhibitors in the treatment of HBV-HCC remain to be exploited. Here, we describe the basic characteristics and development of HBV-HCC and introduce current treatment strategies for HBV-HCC. Of note, we review the principles of immune checkpoint molecules, such as programmed cell death protein 1(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in HBV-HCC, as well as related inhibitors being considered in the clinic. We also discuss the benefits of immune checkpoint inhibitors in the treatment of HBV-HCC and the efficacy of those inhibitors in HCC with various etiologies, aiming to provide insights into the use of immune checkpoint inhibitors for the treatment of HBV-HCC. |
format | Online Article Text |
id | pubmed-10059020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100590202023-03-30 Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy Zhang, Jin Hu, Changwei Xie, Xiaoxiao Qi, Linzhi Li, Chuanzhou Li, Shangze Vaccines (Basel) Review Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide. Surgery, liver transplantation, and ablation therapies have been used to treat early HBV-caused HCC (HBV-HCC); meanwhile, in the advanced stage, chemoradiotherapy and drug-targeted therapy are regularly considered, but with limited efficacy. Recently, immunotherapies, such as tumor vaccine therapy, adoptive cell transfer therapy, and immune checkpoint inhibitor therapy, have demonstrated promising efficacy in cancer treatment. In particular, immune checkpoint inhibitors can successfully prevent tumors from achieving immune escape and promote an anti-tumor response, thereby boosting the therapeutic effect in HBV-HCC. However, the advantages of immune checkpoint inhibitors in the treatment of HBV-HCC remain to be exploited. Here, we describe the basic characteristics and development of HBV-HCC and introduce current treatment strategies for HBV-HCC. Of note, we review the principles of immune checkpoint molecules, such as programmed cell death protein 1(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in HBV-HCC, as well as related inhibitors being considered in the clinic. We also discuss the benefits of immune checkpoint inhibitors in the treatment of HBV-HCC and the efficacy of those inhibitors in HCC with various etiologies, aiming to provide insights into the use of immune checkpoint inhibitors for the treatment of HBV-HCC. MDPI 2023-03-08 /pmc/articles/PMC10059020/ /pubmed/36992198 http://dx.doi.org/10.3390/vaccines11030614 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Zhang, Jin Hu, Changwei Xie, Xiaoxiao Qi, Linzhi Li, Chuanzhou Li, Shangze Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy |
title | Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy |
title_full | Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy |
title_fullStr | Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy |
title_full_unstemmed | Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy |
title_short | Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy |
title_sort | immune checkpoint inhibitors in hbv-caused hepatocellular carcinoma therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059020/ https://www.ncbi.nlm.nih.gov/pubmed/36992198 http://dx.doi.org/10.3390/vaccines11030614 |
work_keys_str_mv | AT zhangjin immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy AT huchangwei immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy AT xiexiaoxiao immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy AT qilinzhi immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy AT lichuanzhou immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy AT lishangze immunecheckpointinhibitorsinhbvcausedhepatocellularcarcinomatherapy |